MX2010005057A - Metodos y composiciones para uso de diagnostico en pacientes de cancer. - Google Patents

Metodos y composiciones para uso de diagnostico en pacientes de cancer.

Info

Publication number
MX2010005057A
MX2010005057A MX2010005057A MX2010005057A MX2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A MX 2010005057 A MX2010005057 A MX 2010005057A
Authority
MX
Mexico
Prior art keywords
methods
compositions
cancer patients
diagnostic use
cancer
Prior art date
Application number
MX2010005057A
Other languages
English (en)
Spanish (es)
Inventor
Thomas D Wu
Daniel S Chen
Couter Jennifer Le
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010005057A publication Critical patent/MX2010005057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2010005057A 2007-11-09 2008-11-05 Metodos y composiciones para uso de diagnostico en pacientes de cancer. MX2010005057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98688407P 2007-11-09 2007-11-09
PCT/US2008/082456 WO2009061800A2 (en) 2007-11-09 2008-11-05 Methods and compositions for diagnostic use in cancer patients

Publications (1)

Publication Number Publication Date
MX2010005057A true MX2010005057A (es) 2010-05-19

Family

ID=40342593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005057A MX2010005057A (es) 2007-11-09 2008-11-05 Metodos y composiciones para uso de diagnostico en pacientes de cancer.

Country Status (13)

Country Link
US (2) US20090123930A1 (enExample)
EP (1) EP2222874A2 (enExample)
JP (1) JP2011502513A (enExample)
KR (1) KR20100095571A (enExample)
CN (1) CN101910416A (enExample)
AU (1) AU2008324782A1 (enExample)
BR (1) BRPI0817158A2 (enExample)
CA (1) CA2703258A1 (enExample)
IL (1) IL205246A0 (enExample)
MX (1) MX2010005057A (enExample)
RU (1) RU2010123381A (enExample)
WO (1) WO2009061800A2 (enExample)
ZA (1) ZA201002808B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766403A1 (en) * 2009-07-13 2011-01-20 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
WO2011033006A1 (en) * 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
JP2013538338A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗癌治療への応答可能性の増大した患者を同定する方法
SG10201505593VA (en) * 2010-07-19 2015-09-29 Hoffmann La Roche Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
EP2802346B1 (en) * 2012-01-13 2018-09-12 F.Hoffmann-La Roche Ag Biological markers for identifying patients for treatment with vegf antagonists
KR20150024342A (ko) * 2012-06-26 2015-03-06 에프. 호프만-라 로슈 아게 유방암을 치료하기 위한 베바시주맙 조합 요법에 대한 혈장 바이오마커
US11091809B2 (en) 2012-12-03 2021-08-17 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
EP3230498B1 (en) * 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
KR101903522B1 (ko) * 2015-11-25 2018-11-23 한국전자통신연구원 다차원 건강데이터에 대한 유사사례 검색 방법 및 그 장치
TW202528738A (zh) * 2023-11-09 2025-07-16 昇捷生物科技股份有限公司 基於α-1抗胰蛋白酶生物標記物之癌症檢測方法及套組

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027216A1 (en) * 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
CA2604549A1 (en) * 2005-04-13 2006-10-19 Oncotest Gmbh Gene expression profiles being predictive for the response of tumors to pharmaceutically effective compounds
CA2648106A1 (en) * 2006-03-31 2007-11-01 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Also Published As

Publication number Publication date
KR20100095571A (ko) 2010-08-31
EP2222874A2 (en) 2010-09-01
US20110151468A1 (en) 2011-06-23
CN101910416A (zh) 2010-12-08
ZA201002808B (en) 2011-07-27
IL205246A0 (en) 2010-12-30
CA2703258A1 (en) 2009-05-14
JP2011502513A (ja) 2011-01-27
US20090123930A1 (en) 2009-05-14
AU2008324782A1 (en) 2009-05-14
RU2010123381A (ru) 2011-12-20
WO2009061800A2 (en) 2009-05-14
WO2009061800A3 (en) 2009-07-16
BRPI0817158A2 (pt) 2015-04-14

Similar Documents

Publication Publication Date Title
MX2018011832A (es) Metodos y composiciones para uso en diagnostico de pacientes con cancer.
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
MX2012002909A (es) Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
PT3130923T (pt) Métodos terapêuticos relacionados com células estaminais
IL190733A0 (en) Methods and compositions for use in treatment of patients with autoantibody positive diseases
GB0708761D0 (en) Improvements in and relating to medical instruments
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MY160041A (en) Compositions and methods for treating parasitic infections
IL206079A0 (en) Microrna expression profiling and targeting in peripheral blood in lung cancer
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
MX2008012754A (es) Composiciones de anticuerpos y metodos para tratamiento de enfermedad neoplastica.
LT2282758T (lt) Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
IL206748A (en) Molecular test for @cancer @ breast cancer @
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
NZ584606A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2010054377A3 (en) Fully human antibodies against n-cadherin
MX2013003599A (es) Interferon-beta para uso como monoterapia o en combinacion con otras terapias de cancer.
PT2320900T (pt) Utilização de opioides ou miméticos de opioides para o tratamento de pacientes com cancros resistentes
MX358726B (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
IL217209A0 (en) Novel antibodies and their uses in therapeutic and diagnostic methods
GB2465907A (en) VHZ for diagnosis and treatment of cancer
EP2294197A4 (en) HHIP1 PROTEIN VERSION AND METHOD AND USES THEREOF

Legal Events

Date Code Title Description
FA Abandonment or withdrawal